1st Quarter - Report

XOMA CORPORATION (FKA XOMA (US) LLC) for XOMA CORPORATION (FKA XOMA (US) LLC)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$110,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2010 $110,000 Replaced
1st Quarter - Amendment Oct 19, 2010 $120,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Issues relating to biodefense and national security strategy, specifically including Anti-Botulinum toxin medical countermeasures.

LobbyistCovered position, as disclosed
BETH RADA —
PATRICK JEROME SCANNON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

FY2011 defense appropriations, provisions relating to biodefense and anti-botulinum toxin medical countermeasures.

LobbyistCovered position, as disclosed
BETH RADA —
PATRICK JEROME SCANNON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.